AR120727A1 - Composición farmacéutica que comprende bpi-7711 y método de preparación de la misma - Google Patents

Composición farmacéutica que comprende bpi-7711 y método de preparación de la misma

Info

Publication number
AR120727A1
AR120727A1 ARP200103449A ARP200103449A AR120727A1 AR 120727 A1 AR120727 A1 AR 120727A1 AR P200103449 A ARP200103449 A AR P200103449A AR P200103449 A ARP200103449 A AR P200103449A AR 120727 A1 AR120727 A1 AR 120727A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
preparation
same
bpi
comprises bpi
Prior art date
Application number
ARP200103449A
Other languages
English (en)
Spanish (es)
Inventor
Chengwu Yu
Xin Li
Chun Tang
Xiaoxia Zhang
Jirong Peng
Don Zhang
Yuelie Lu
Original Assignee
Beta Pharma Suzhou Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Suzhou Ltd filed Critical Beta Pharma Suzhou Ltd
Publication of AR120727A1 publication Critical patent/AR120727A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP200103449A 2019-12-11 2020-12-11 Composición farmacéutica que comprende bpi-7711 y método de preparación de la misma AR120727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911264353.1A CN110898026A (zh) 2019-12-11 2019-12-11 包含bpi-7711的药用组合物及其制备方法

Publications (1)

Publication Number Publication Date
AR120727A1 true AR120727A1 (es) 2022-03-09

Family

ID=69824307

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103449A AR120727A1 (es) 2019-12-11 2020-12-11 Composición farmacéutica que comprende bpi-7711 y método de preparación de la misma

Country Status (4)

Country Link
CN (1) CN110898026A (zh)
AR (1) AR120727A1 (zh)
TW (1) TW202122087A (zh)
WO (1) WO2021115425A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110898026A (zh) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 包含bpi-7711的药用组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
EP3471730B1 (en) * 2016-06-17 2021-10-20 Beta Pharma, Inc. Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
EP3638241B1 (en) * 2017-06-16 2022-05-25 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN110898026A (zh) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 包含bpi-7711的药用组合物及其制备方法

Also Published As

Publication number Publication date
WO2021115425A1 (zh) 2021-06-17
TW202122087A (zh) 2021-06-16
CN110898026A (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
MX2022015207A (es) Compuestos antivirales para tratar infecciones por coronavirus, picornavirus, y norovirus.
MX2022008066A (es) Compuestos triciclicos sustituidos.
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
JOP20190070A1 (ar) مركبات بنزو[b] ثيوفين كناهضات محفزة لبروتين جينات الإنترفيرون
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
EA201201496A1 (ru) Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201990455A1 (ru) КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2024000299A (es) Compuestos antivirales.
WO2018125961A8 (en) Poly-adp ribose polymerase (parp) inhibitors
MX2022005615A (es) Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
AR120727A1 (es) Composición farmacéutica que comprende bpi-7711 y método de preparación de la misma
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
MX2022008487A (es) Degradadores de smarca2-vhl.

Legal Events

Date Code Title Description
FB Suspension of granting procedure